121 related articles for article (PubMed ID: 36715555)
1. Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy.
Moritoh K; Shoji K; Amagai Y; Fujiyuki T; Sato H; Yoneda M; Kai C
Cancer Sci; 2023 May; 114(5):2158-2168. PubMed ID: 36715555
[TBL] [Abstract][Full Text] [Related]
2. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.
Tamura K; Fujiyuki T; Moritoh K; Akimoto H; Iizuka K; Sato H; Asano K; Yoneda M; Kai C
Sci Rep; 2023 Oct; 13(1):18168. PubMed ID: 37875555
[TBL] [Abstract][Full Text] [Related]
4. A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.
Fujiyuki T; Yoneda M; Amagai Y; Obayashi K; Ikeda F; Shoji K; Murakami Y; Sato H; Kai C
Oncotarget; 2015 Sep; 6(28):24895-903. PubMed ID: 26317644
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C
Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781
[TBL] [Abstract][Full Text] [Related]
6. Development of new therapy for canine mammary cancer with recombinant measles virus.
Shoji K; Yoneda M; Fujiyuki T; Amagai Y; Tanaka A; Matsuda A; Ogihara K; Naya Y; Ikeda F; Matsuda H; Sato H; Kai C
Mol Ther Oncolytics; 2016; 3():15022. PubMed ID: 27119113
[TBL] [Abstract][Full Text] [Related]
7. Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells.
Awano M; Fujiyuki T; Shoji K; Amagai Y; Murakami Y; Furukawa Y; Sato H; Yoneda M; Kai C
Cancer Sci; 2016 Nov; 107(11):1647-1652. PubMed ID: 27561180
[TBL] [Abstract][Full Text] [Related]
8. Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy.
Fujiyuki T; Amagai Y; Shoji K; Kuraishi T; Sugai A; Awano M; Sato H; Hattori S; Yoneda M; Kai C
Mol Ther Oncolytics; 2020 Dec; 19():127-135. PubMed ID: 33145396
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.
Amagai Y; Fujiyuki T; Yoneda M; Shoji K; Furukawa Y; Sato H; Kai C
Sci Rep; 2016 Apr; 6():24572. PubMed ID: 27090874
[TBL] [Abstract][Full Text] [Related]
10. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains.
Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY
Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409
[TBL] [Abstract][Full Text] [Related]
11. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma.
Lal S; Raffel C
Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698
[TBL] [Abstract][Full Text] [Related]
12. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
[TBL] [Abstract][Full Text] [Related]
13. Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3/GSDME-mediated pyroptosis.
Wu A; Li Z; Wang Y; Chen Y; Peng J; Zhu M; Li Y; Song H; Zhou D; Zhang C; Lv Y; Zhao Z
Cell Death Discov; 2023 May; 9(1):171. PubMed ID: 37202386
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
15. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
17. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
18. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
[TBL] [Abstract][Full Text] [Related]
20. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
